REGN34.SA
Regeneron Pharmaceuticals, Inc.
São PauloBRLEQUITY
Healthcare
DELAYED
Last price
71.82
▲ 0.24 (0.34%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
71.60
Prev close
71.58
Day high
72.80
Day low
71.60
Volume
327
Market cap
$443.65B
P/E (TTM)
20.52
52W range
49.24 – 73.33
Day trading desk
Gap from prior close
+0.03%
Prior close 71.58
VWAP
72.72
-1.24% from price
Relative volume
0.45×
Quiet session
Session range
1.68%
71.60 – 72.80
Position in range
18%
Near session low
ATR (14D)
1.94
2.70% of price
Prior day high
72.58
PDH
Prior day low
71.48
PDL
Bid / ask spread
—
Quote not published
Session volume
314
Avg 699
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+11.18%
+12.4%
1M
+28.96%
+25.6%
3M
+34.80%
+32.4%
6M
+6.23%
-5.7%
YTD
+1.28%
-10.7%
1Y
+33.74%
+13.6%
3Y
+9.45%
-65.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on REGN34.SA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$443.65B
Enterprise value$415.16B
Revenue (TTM)$15.53B
Gross profit$6.91B
EBITDA$4.70B
Net income$4.33B
EPS (TTM)$3.50
Free cash flow$3.07B
Total cash$7.99B
Total debt$2.71B
Book value / share$27.92
Shares outstanding6.07B
Float5.63B
Short % of float—
Dividend yield0.31%
Beta (5Y)0.19
Valuation & profitability ratios
Trailing P/E20.52
Forward P/E—
PEG ratio1.36
Price / sales—
Price / book2.57
EV / revenue26.73
EV / EBITDA88.29
Gross margin44.46%
Operating margin33.11%
Profit margin27.87%
Return on equity14.04%
Return on assets6.53%
Debt / equity8.54
Current ratio3.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $14.34B | $14.20B | $13.12B | $12.17B | +1.0% |
| Operating revenue | $13.64B | $13.69B | $12.58B | $11.81B | -0.3% |
| Cost of revenue | $2.10B | $1.97B | $1.82B | $1.56B | +6.6% |
| Gross profit | $12.24B | $12.23B | $11.30B | $10.61B | +0.1% |
| Research & development | $5.85B | $5.23B | $4.63B | $3.85B | +11.8% |
| Selling, general & admin | $2.70B | $2.95B | $2.63B | $2.12B | -8.6% |
| Total operating expense | $8.54B | $8.24B | $7.25B | $5.87B | +3.6% |
| Operating income | $3.70B | $3.99B | $4.05B | $4.74B | -7.2% |
| Net interest income | $673.00M | $656.20M | $422.90M | $100.70M | +2.6% |
| Pre-tax income | $5.23B | $4.78B | $4.20B | $4.86B | +9.4% |
| Tax provision | $725.80M | $367.30M | $245.70M | $520.40M | +97.6% |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | +2.1% |
| Net income to common | $4.50B | $4.41B | $3.95B | $4.34B | +2.1% |
| Basic EPS | 0.72 | 0.68 | 0.62 | 0.68 | +5.3% |
| Diluted EPS | 0.69 | 0.64 | 0.58 | 0.64 | +8.2% |
| EBIT | $5.27B | $4.84B | $4.27B | $4.92B | +9.1% |
| EBITDA | $5.82B | $5.32B | $4.69B | $5.26B | +9.4% |
| Basic shares | 6.28B | 6.47B | 6.40B | 6.43B | -3.1% |
| Diluted shares | 6.52B | 6.91B | 6.82B | 6.81B | -5.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.12B | $2.49B | $2.73B | $3.11B | +25.3% |
| Cash & short-term investments | $8.61B | $9.01B | $10.84B | $7.74B | -4.5% |
| Accounts receivable | $5.74B | $6.21B | $5.67B | $5.33B | -7.6% |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | +3.7% |
| Total current assets | $18.02B | $18.66B | $19.48B | $15.88B | -3.4% |
| Property, plant & equipment | $5.12B | $4.60B | $4.15B | $3.76B | +11.3% |
| Goodwill & intangibles | $1.26B | $1.15B | $1.04B | $915.50M | +9.5% |
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | +7.4% |
| Total current liabilities | $4.37B | $3.94B | $3.42B | $3.14B | +10.8% |
| Long-term debt | $1.99B | $1.98B | $1.98B | $1.98B | +0.1% |
| Total debt | $2.71B | $2.70B | $2.70B | $2.70B | +0.1% |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | +10.7% |
| Retained earnings | $35.80B | $31.67B | $27.26B | $23.31B | +13.0% |
| Shareholder equity | $31.26B | $29.35B | $25.97B | $22.66B | +6.5% |
| Working capital | $13.65B | $14.72B | $16.06B | $12.74B | -7.2% |
| Net tangible assets | $30.00B | $28.20B | $24.93B | $21.75B | +6.4% |
| Shares issued | 139.42M | 137.82M | 134.92M | 132.20M | +1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | +2.1% |
| Depreciation & amortisation | $543.70M | $482.90M | $421.00M | $341.40M | +12.6% |
| Stock-based compensation | $993.70M | $982.80M | $885.00M | $725.00M | +1.1% |
| Change in working capital | $532.60M | -$618.30M | -$94.10M | -$243.30M | +186.1% |
| Operating cash flow | $4.98B | $4.42B | $4.59B | $5.01B | +12.6% |
| Capital expenditure | -$1.21B | -$881.60M | -$926.40M | -$1.62B | -37.7% |
| Investing cash flow | -$629.10M | -$2.47B | -$3.19B | -$3.78B | +74.5% |
| Share buybacks | -$3.97B | -$3.63B | -$2.94B | -$2.53B | -9.3% |
| Dividends paid | -$370.30M | $0 | $0 | — | — |
| Financing cash flow | -$3.72B | -$2.20B | -$1.79B | -$1.01B | -68.8% |
| Free cash flow | $3.77B | $3.54B | $3.67B | $3.40B | +6.4% |
| End cash position | $3.12B | $2.49B | $2.74B | $3.12B | +25.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | — | +19.0% |
| Operating revenue | $4.10B | $3.43B | $3.65B | $3.56B | $3.49B | — | +19.3% |
| Cost of revenue | $576.50M | $669.40M | $584.60M | $521.60M | $530.20M | — | -13.9% |
| Gross profit | $3.71B | $2.94B | $3.30B | $3.23B | $3.15B | — | +26.5% |
| Research & development | $1.63B | $1.54B | $1.63B | $1.48B | $1.43B | — | +5.7% |
| Selling, general & admin | $662.10M | $647.70M | $775.00M | $657.80M | $634.20M | — | +2.2% |
| Total operating expense | $2.29B | $2.19B | $2.40B | $2.12B | $2.07B | — | +4.7% |
| Operating income | $1.42B | $744.80M | $898.60M | $1.11B | $1.08B | — | +90.7% |
| Net interest income | $172.30M | $170.60M | $181.10M | $155.80M | $171.20M | — | +1.0% |
| Pre-tax income | $1.53B | $831.20M | $1.04B | $1.76B | $1.52B | — | +83.8% |
| Tax provision | $230.90M | $104.00M | $199.10M | $303.30M | $127.10M | — | +122.0% |
| Net income | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | — | +78.3% |
| Net income to common | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | — | +78.3% |
| Basic EPS | 0.21 | 0.12 | 0.14 | — | 0.22 | 0.13 | +80.5% |
| Diluted EPS | 0.20 | 0.11 | 0.13 | — | 0.21 | 0.12 | +81.2% |
| EBIT | $1.54B | $844.10M | $1.06B | $1.78B | $1.52B | — | +82.3% |
| EBITDA | $1.66B | $967.30M | $1.20B | $1.92B | $1.66B | — | +71.9% |
| Basic shares | 6.17B | 6.24B | 6.17B | — | 6.31B | 6.40B | -1.2% |
| Diluted shares | 6.36B | 6.46B | 6.45B | — | 6.52B | 6.67B | -1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | -17.1% |
| Cash & short-term investments | $7.99B | $8.75B | $8.61B | $8.44B | $7.47B | -8.7% |
| Accounts receivable | $6.57B | $5.73B | $5.74B | $5.69B | $5.61B | +14.6% |
| Inventory | $3.08B | $3.10B | $3.20B | $3.25B | $3.21B | -0.6% |
| Total current assets | $18.45B | $18.21B | $18.02B | $17.98B | $16.86B | +1.3% |
| Property, plant & equipment | $5.46B | $5.27B | $5.12B | $5.00B | $4.84B | +3.7% |
| Goodwill & intangibles | $1.31B | $1.29B | $1.26B | $1.38B | $1.35B | +1.8% |
| Total assets | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | +2.1% |
| Total current liabilities | $5.53B | $5.11B | $4.37B | $4.43B | $3.67B | +8.3% |
| Long-term debt | $1.99B | $1.99B | $1.99B | $1.99B | $1.99B | +0.0% |
| Total debt | $2.71B | $2.71B | $2.71B | $2.71B | $2.71B | +0.0% |
| Total liabilities | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | +6.1% |
| Retained earnings | $37.62B | $36.42B | $35.80B | $35.05B | $33.68B | +3.3% |
| Shareholder equity | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | +0.9% |
| Working capital | $12.92B | $13.10B | $13.65B | $13.56B | $13.19B | -1.4% |
| Net tangible assets | $30.40B | $30.14B | $30.00B | $29.58B | $28.59B | +0.9% |
| Shares issued | 103.14M | 139.72M | 139.42M | 138.02M | 138.02M | -26.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | +78.3% |
| Depreciation & amortisation | $123.70M | $123.20M | $145.00M | $136.70M | $135.10M | +0.4% |
| Stock-based compensation | $243.00M | $257.40M | $249.30M | $237.00M | $251.70M | -5.6% |
| Change in working capital | -$649.20M | $36.50M | $5.90M | $625.00M | -$227.90M | -1,878.6% |
| Operating cash flow | $813.00M | $1.08B | $1.17B | $1.62B | $1.14B | -24.6% |
| Capital expenditure | -$291.20M | -$279.50M | -$290.70M | -$244.70M | -$406.80M | -4.2% |
| Investing cash flow | -$92.70M | -$428.90M | $220.30M | -$402.90M | -$1.09B | +78.4% |
| Share buybacks | -$1.18B | -$867.50M | -$1.19B | -$667.00M | -$1.07B | -35.7% |
| Dividends paid | -$96.80M | -$97.80M | -$92.70M | -$91.20M | -$92.60M | +1.0% |
| Financing cash flow | -$1.22B | -$802.20M | -$780.10M | -$717.90M | -$1.13B | -52.7% |
| Free cash flow | $521.80M | $799.40M | $880.00M | $1.37B | $737.60M | -34.7% |
| End cash position | $2.47B | $2.97B | $3.12B | $2.51B | $2.02B | -17.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $4.54B | +21.0% |
| Next quarter | — | — | $4.63B | +19.2% |
| Current year | — | — | $16.92B | +18.0% |
| Next year | — | — | $18.42B | +8.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions0.00%
Institutions holding6
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
70.10
+2.46% from price
SMA 20
66.97
+7.23% from price
SMA 50
60.00
+19.70% from price
SMA 100
58.93
+21.87% from price
SMA 200
62.60
+14.73% from price
EMA 12
69.37
+3.54% from price
EMA 26
65.82
+9.12% from price
EMA 50
62.57
+14.78% from price
RSI (14)
67.9
Neutral
MACD (12,26,9)
3.55
Hist 0.24
ATR (14)
1.94
2.70% of price
Realised vol 30D
43.0%
Annualised
Bollinger upper
75.16
20, 2σ
Bollinger lower
58.79
20, 2σ
50 / 200 cross
Death
60.00 vs 62.60
Trend bias
Above 200
+14.73%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.14
Less volatile than market
Correlation to SPY
-0.04
Largely independent
Realised vol 30D
43.0%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-31.2%
Peak to trough
Max drawdown 5Y
-59.5%
Peak to trough
ATR 14
1.94
2.70% of price
Beta (reported)
0.19
5Y monthly, from filing
Dividends & splits
Forward rate$0.22 / yr
Forward yield0.31%
5-year avg yield—
Payout ratio6.40%
Ex-dividend dateAug 17, 2026
Next pay date—
Last split12:1
Split dateNov 28, 2022
Headlines
Centre Table and Chair Rentals See Rising Demand in Pune, Hyderabad and Chennai in 2026 as ₹8,000–₹18,000 Purchases Shift Toward ₹86/Month Plans From Platforms Like Rentomojo
GlobeNewswire · 5m ago
Total Voting Rights and Transaction in Own Shares
GlobeNewswire · 6m ago
Paychex Expands Award-Winning Lifestyle Benefits to 2M+ Employees on the Paycor® Platform
GlobeNewswire · 6m ago
REVOLVE Unveils the Porsche Collection by REVOLVE
PR Newswire · 6m ago
Luxor Energy and Bentaus Complete First AI GPU Response to ERCOT 4CP Signals
PR Newswire · 6m ago
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
GlobeNewswire · 6m ago
Oppenheimer Hires Bruce Rideaux and Promotes Lauren Carter As Public Finance Business Continues to Expand
PR Newswire · 6m ago
Mesirow's Andrew Mutlu Discusses Roth Strategies and Tax Diversification on WGN Radio
PR Newswire · 6m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.